dpp4i and glp 1 agonist GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? Table 2 from DPP- 4
Description
absolute risk reduction, 7.49%)

They offer real, life-changing benefits for manyyet come with side effects, high costs, and long-term uncertainties

& Brubaker, M

Given the vast number of incretin-based medications under development, mainly aiming at higher efficacy in body weight reduction, one may overlook that adherence to, and persistence of, therapy with GLP-1RAs in real-world studies is relatively low (18, 126)

Semaglutide withdrawal symptoms when stopping the medication are similar to those experienced with tirzepatide, including appetite return and potential weight regain if proper strategies are not implemented
